Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Acute kidney injury occurs in up to 30% of patients undergoing cardiac surgery. Cardiac surgery associated-acute kidney injury (CSA-AKI) is characterized by a sudden and sustained decrease in renal function with insufficient elimination waste products. The problem is that postoperative diagnosis of CSA-AKI is delayed because it relies solely upon the slow and unreliable rise in serum creatinine (SCr) levels that may lead to delayed start in treatment and increased risk of adverse outcomes. We hypothesize that Matrix Metalloproteins (MMPs) -2, -9 and Neutrophil gelatinase-associated lipocalin (NGAL) are associated with and earlier detectors of CSA-AKI compared to levels of SCr.
Cardiopulmonary bypass (CPB), although essential to the performance of most cardiac operations, has been shown to cause injury to other organs, particularly to the kidneys and brain. Matrix Metalloproteins (MMPs) are ubiquitous proteolytic enzymes that degrade extracellular matrix and have been shown to be involved in injury to transplant kidneys. To date, no interventions are available to decrease the risk of cardiac surgery associated-acute kidney injury (CSA-AKI).
NGAL is a known indicator of injury to kidney, thus making it a promising biomarker for CSA-AKI. It may be that a single biomarker will not be sensitive and specific across the spectrum of CSA-AKI. This research investigates MMP-2, -9 and Neutrophil gelatinase-associated lipocalin (NGAL) and their association with and earlier detection of CSA-AKI compared to levels of SCr.
We hypothesize that increased activity of MMPs are associated with CSA-AKI. Furthermore, MMP-2 and/ or -9 may be predictors and/ or biomarkers for the early detection of CSA-AKI compared to serum levels of creatinine.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| CSA-AKI | Patients that developed cardiac surgery-associated Acute Kidney Injury | ||
| non CSA-AKI | Patients that did not developed cardiac surgery-associated Acute Kidney Injury |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Increased MMP-2 and -9 in patients that develop CSA-AKI | Increased MMP-2 and -9 activity in serum and or urine in patients that develop CSA-AKI | Pre-CPB, 10 min post-CPB time point, 4 hours post-CPD |
| Measure | Description | Time Frame |
|---|---|---|
| Increased NGAL levels in patients that develop CSA-AKI | Increased NGAL levels in serum and or urine in patients that develop CSA-AKI | Pre-CPB, 10 min post-CPB time point, 4 hours post-CPD |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Approached as a prospective study male and female patients undergoing cardiopulmonary bypass-supported cardiac surgery were recruited and signed a written consent agreeing to participate in this research.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Erick D McNair, PhD | Contact | 306 966-7637 | erick.mcnair@usask.ca | |
| Mike Moser, MD | Contact | 306 655-5320 | mike.moser@usask.ca |
| Name | Affiliation | Role |
|---|---|---|
| Erick D McNair, PhD | University of Saskatchewan | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Saskatchewan | Recruiting | Saskatoon | Saskatchewan | S7N 0W8 | Canada |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided